GlassScriptPhysician profile
Chandler R Hutton
NPI 1033756168
$3,508.89
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $157 · 2022: $82.40 · 2023: $2,152 · 2024: $1,118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,010 · Food and Beverage: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,010.00 |
| Food and Beverage | $259.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $3,063.47 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $63.29 | 2022-2024 | Fasenra, Airsupra |
| Aimmune Therapeutics, INC. | $59.86 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.03 | 2021 | |
| Octapharma USA, INC. | $37.41 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $32.19 | 2023-2024 | Dupixent |
| Amgen INC. | $31.32 | 2023-2024 | Tezspire |
| Genentech USA, INC. | $29.53 | 2021-2024 | Xolair |
| Incyte Corporation | $26.64 | 2022-2023 | Opzelura |
| Genzyme Corporation | $25.10 | 2022-2024 | |
| Glaxosmithkline, LLC. | $23.55 | 2023 | Nucala |
| Phadia US INC. | $18.57 | 2023 | Immunocap |
| Kaleo, INC. | $16.99 | 2021 | |
| Blueprint Medicines Corporation | $16.79 | 2024 | Ayvakit |
| Teva Pharmaceuticals USA, INC. | $14.15 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chandler Hutton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.